Navilas® for Patients
OD-OS Global
Ask a Question
menu

Diabetic Macular Edema

Introducing a Better Treatment Paradigm for Patients and Physicians

Navilas benefits for treatment of clinically significant macular edema have been evaluated in multiple studies world-wide.

These studies demonstrate a significant increase in accuracy, which in synergy with a more complete treatment has been basis for a faster onset of the treatment effect and an overall reduction in laser re-treatments. 

Adding these benefits to anti-VEGF therapy has been shown to reduce the required number of injections while maintaining visual acuity gains achieved by the anti-VEGF treatments.

Higher Efficacy

Higher Accuracy +28 %

Kernt et al. as well as Kozak et al. demonstrate an increased accuracy and precision through image-guided laser pre-positioning (1,2).

Less Retreatments -42%

Navilas enables a better completeness of retinal laser treatment through standardized digital planning and documentation, thus resulting in a more durable treatment with lower retreatment rates in laser monotherapy. (3)

Faster Efficacy

Earlier onset of anatomical effect

Navilas provides a faster reduction in central retinal thickness when compared to conventional lasers. Additionally a trend towards a larger reduction in central retinal thickness when compared to conventional laser has been demonstrated by Singh et al. (4)

Earlier onset of functional effects

As observed by Neubauer et al. navigated laser enables faster visual acuity gains to the patient's benefit. (3)

Reducing Treatment Burden

Reduced re-injection rate

Navigated laser combination therapy and ranibizumab monotherapy similarly improved mean BCVA letter score (+8.41 vs. +6.31 letters, p=0.258). In the combination group significantly less injections were required after the 3 injection loading phase (0.88±1.23 vs. 3.88±2.32, p<0.001) (5,6)

Navigated Laser reduces retreatment rate

Two studies using navigated laser in combination with anti-VEGF demonstrated a significant reduction in injections. Even though cross-trial comparisons need to be interpreted with caution, this benefit has not been demonstrated with conventional, non-navigated laser systems, supporting the unique benefits of navigated laser delivery. 

References

  1. Clinical Evaluation and Treatment Accuracy in DiabeticMacular Edema Using Navigated Laser Photocoagulator NAVILAS. Kozak I, Oster SF, Cortes MA, Dowell D, Hartmann K, Kim JS, Freeman WR. Ophthalmology. 2011 Jan 24
    Read more
  2. Pain and accuracy of focal laser treatment for diabetic macular edema using a retinal navigated laser (Navilas).  Kernt M, CheuteuRE, Cserhati S, Seidensticker F, Liegl RG, Lang J, Haritoglou C, Kampik A, Ulbig MW, Neubauer AS. Clin Ophthalmol. 2012;06:289-96
    Read more
  3. Navigated macular laser decreases retreatment rate for diabetic macular edema: a comparision with conventional macular laser. Neubauer AS, Langer J, Wolf J, Kozak I, Seidensticker F, Ulbig M, Freeman WR, Kampik A, Kernt M.  Clin Ophthalmol. 2013:121-128
    Read More 
  4. From Art to Science in DME Treatment A comparison of anatomical outcomes following navigated OCT-based laser and conventional focal laser treatments.ANG LI, BA • RUMNEEK BEDI, BA • RISHI P. SINGH, MD.  
    Read More
  5. Comparative evaluation of combined navigated laser photocoagulation and intravitreal ranibizumab in the treatment of diabetic macular edema. Liegl R, Langer J, Seidensticker F, Reznicek L, Haritoglou C, Ulbig MW, Neubauer AS, Kampik A, Kernt M.  PLoS One. 2014 Dec 26;9(12)
    Read More
  6. 12-month results of the standardised combination therapy for diabetic macular oedema: intravitreal bevacizumab and navigated retinal photocoagulation. Barteselli G, Kozak I, El-Emam S, Chhablani J, Cortes MA, Freeman WR. Br J Ophthalmol. 2014 Aug;98(8):1036-41. 
    Read More
Company
Legal Notice
For Customers Navilas® Academy